Products
Rilogrotug Biosimilar Monoclonal Antibody (GDF15) for Research
Cat No.: GMP-Bios-INN-1370
Anti-GDF15/MIC1/MIC-1/NAG1/NAG-1/PTGFB therapeutic antibody (Pre-made Rilogrotug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Rilogrotug (development code AV-380) is a humanized monoclonal antibody targeting growth differentiation factor 15 (GDF15), MIC1, MIC-1, NAG1, NAG-1 and PTGFB. It is developed by AVEO Therapeutics and St Vincents Hospital Sydney for Cachexia in Phase I development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1370-1mg | 1mg | 3090 |
| GMP-Bios-INN-1370-10mg | 10mg | |
| GMP-Bios-INN-1370-100mg | 100mg | |
| GMP-Bios-INN-1370-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Rilogrotug biosimilar, Whole mAb, Anti-GDF15/MIC1/MIC-1/NAG1/NAG-1/PTGFB Antibody: Anti-GDF15/Growth/differentiation factor 15/GDF-15 therapeutic antibody |
| INN Name | Rilogrotug |
| Target | GDF15/MIC1/MIC-1/NAG1/NAG-1/PTGFB |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2024 |
| Year Recommended | na |
| Companies | AVEO Therapeutics;St Vincents Hospital Sydney |
| Conditions Approved | na |
| Conditions Active | Cachexia |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
